# Halozyme Therapeutics

Type: Company (HALO)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/halozyme-therapeutics
Canonical HTML page: https://getfinancebrief.com/entity/halozyme-therapeutics

## Recent coverage (2 stories)

### HALO stock hits $103 as FY2026 EPS guidance of $8.65-$9.00 overshoots consensus by $0.63
2026-08-12 02:50:02 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Halozyme Therapeutics posted a massive Q2 beat and raised FY2026 EPS guidance to $8.65-$9.00, well above the $8.02 consensus, triggering a two-day stock surge past $103. With a forward P/E near 11.5x and a PEG ratio of 0.36, the market is repricing the stock after realizing the royalty growth was underestimated.
Full story: https://getfinancebrief.com/story/halozyme-fy2026-earnings-guidance-beat-stock-surge

### Halozyme and Celanese Earnings Misses Signal Margin Pressure Across Sectors
2026-02-19 04:48:54 · Sentiment: Bearish · Impact: 6/10 · Sources: 3

A wave of earnings reports from Halozyme Therapeutics, Celanese, and OneSpaWorld has revealed significant bottom-line misses, highlighting growing cost pressures and demand volatility. While Halozyme managed a revenue beat, its massive EPS shortfall points to substantial operational or one-time headwinds that are rattling investor confidence.
Full story: https://getfinancebrief.com/story/halozyme-celanese-onespaworld-earnings-miss-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.